Six years later, SEC drops claims of accounting fraud against biotech exec
The US Securities and Exchange Commission has dropped its claims against the former CEO of Osiris Therapeutics, who was accused of lying about the regenerative medicine player’s financial performance.
All claims against Lode Debrabandere have been dismissed, according to a court filing from late November, capping a legal saga that goes all the way back to 2017.
“The SEC’s allegations had no merit, and the complete dismissal is the only correct, fair, and just outcome,” Debrabandere wrote in an email to Endpoints News. “I am grateful that the SEC ultimately recognized it should drop the action against me.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters